In contrast, it has been documented that IL‐6R blockade mediated by Tocilizumab significantly attenuated organ dysfunction and improved prognosis of SIRS/sepsis via NF‐κB inhibition.19 This evidence concerns the gene IL6R and systemic inflammatory response syndrome.